Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders

Laboratory Investigation

Volumn 75, Issue 4, 1996, Pages 575-588

  Smir, Bassam N ^a   Hauke, Ralph J ^a   Bierman, Philip J ^a   Gross, Thomas G ^a   D'Amore, Francesco ^a   Anderson, James R ^b   Greiner, Timothy C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN;

ARTICLE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; SURVIVAL; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; BLOTTING, SOUTHERN; CHILD; CHILD, PRESCHOOL; CLONING, MOLECULAR; FEMALE; GENE DELETION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, VIRAL; ORGAN TRANSPLANTATION; SURVIVAL ANALYSIS; VIRAL MATRIX PROTEINS;

EID: 0029973923     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Séguin C, Tuffnell PS, and Barrell BG (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207-211.
2. Bhatia S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, and Neglia JP (1996). Malignant neoplasms following bone marrow transplantation. Blood 87:3633-3639.
3. Bierman PJ, Vose JM, Langnas AN, Rifkin RM, Hauke RJ, Smir BN, and Greiner TC (1996). Hodgkin's disease following solid organ transplantation. Ann Oncol 7:265-270.
4. Chang Y-S, Su I-J, Chung P-J, Shu C-H, Ng C-K, Wu S-J, and Liu S-T (1995). Detection of an Epstein-Barr virus variant in T-cell lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 62:673-677.
5. Chen M-L, Tsai C-N, Liang C-L, Shu C-H, Huang C-R, Sulitzeanu D, Liu S-T, and Chang Y-S (1992). Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131-2140.
6. Chen W-G, Chen Y-Y, Bacchi MM, Bacchi CE, Alvarenga M, and Weiss LM (1996). Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue: Type A with a high prevalence of deletions within the latent membrane protein gene. Am J Pathol 148:17-23.
7. d'Amore F, Johansen P, Houmand A, Weisenburger DD, and Mortensen LS (1996). Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: Highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 87: 1045-1055.
8. Delecluse H-J, Kremmer E, Rouault J-P, Cour C, Bornkamm G, and Berger F (1995). The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 146:1113-1120.
9. Dhir RK, Nalesnik MA, Demetris AJ, and Randhawa PS (1995). Latent membrane protein expression in posttransplant lymphoproliferative disease. Appl Immunohistochem 3:123-126.
10. Doyle TJ, Venkatachalam KK, Maeda K, Saeed SM, and Tilchen EJ (1983). Hodgkin's disease in renal transplant recipients. Cancer 51:245-247.
11. Epstein MA, Achong BG, and Barr YM (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703.
12. Fennewald S, van Santen V, and Kieff E (1984). Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51:411-419.
13. Frank D, Cesarman E, Liu YF, Michler RE, and Knowles DM (1995). Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 85:1396-1403.
14. Garvin AJ, Self S, Sahovic EA, Stuart RK, and Marchalonis JJ (1988). The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol 12:64-70.
15. Greiner TC, Raffeld M, Lutz C, Dick F, and Jaffe ES (1995). Analysis of T cell receptor-γ gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products: Correlation with tumor-specific sequences. Am J Pathol 146:46-55.
16. Griffith RC, Saha BK, Janney CM, Ratner L, Brunt EM, Gajl-Peczalska KJ, and Hanto DW (1990). Immunoblastic lymphoma of T-cell type in a chronically immunosuppressed renal transplant recipient. Am J Clin Pathol 93:280-285.
17. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker F, Kieff E, and Rickinson A (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115.
18. Henle W and Henle G (1970). Evidence for a relation of Epstein-Barr virus to Burkitt's lymphoma and nasopharyngeal carcinoma. Bibl Haematol 36:706-713.
19. Hennessy K, Fennewald S, Hummel M, Cole T, and Kieff E (1984). A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 81:7207-7211.
20. Hu L-F, Chen F, Zheng X, Ernberg I, Cao S-L, Christensson B, Klein G, and Winberg G (1993). Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575-1583.
21. Hu L-F, Zabarovsky ER, Chen F, Cao S-L, Ernberg I, Klein G, and Winberg G (1991). Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72:2399-2409.
22. Hudson GS, Farrell PJ, and Barrell BG (1985). Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol 53:528-535.
23. Kaplan GL and Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457.
24. Kaye KM, Izumi KM, Mosialos G, and Kieff E (1995). The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: Fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675-683.
25. Kingma DW, Weiss WB, Jaffe ES, Frekko KK, and Raffeld M (1996). Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88:242-251.
26. Knecht H, Bachmann E, Brousset P, Rothenberger S, Einsele H, Lestou VS, Delsol G, Bachmann F, Ambros PF, and Odermatt BF. (1995a). Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523-528.
27. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, and Pallesen G (1993a). Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942.
28. Knecht H, Bachmann E, Joske DJL, Sahli R, Eméry-Goodman A, Casanova J-L, Zilic M, Bachmann F, and Odermatt BF (1993b). Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 7:580-585.
29. Knecht H, Martius F, Bachmann E, Hoffman T, Zimmermann DR, Rothenberger S, Sandvej K, Wegmann W, Hurwitz N, Odermatt BF, Kummer H, and Pallesen G (1995b). A deletion mutant of the LMP1 oncogene of Epstein-Barr virus is associated with evolution of angioimmunoblastic lymphadenopathy into B immunoblastic lymphoma. Leukemia 9:458-465.
30. Knecht H, Raphaël M, McQuain C, Rothenberger S, Pihan G, Camilleri-Broët S, Bachmann E, Kershaw GR, Ryan S, Kittler ELW, Quesenberry PJ, Schlaifer D, Woda BA, and Brousset P (1996). Deletion variants within the NF-κB activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 87:876-881.
31. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, and Michler RE (1995). Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552-565.
32. Labouyrie E, Moprel D, Boiron J-M, Dubus P, Montastruc M, Bloch B, Reiffers J, de Mascarel A, and Merlio J-P (1995). Peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Mod Pathol 8:355-359.
33. Leblond V, Sutton L, Dorent R, Davi F, Bitker M-O, Gabarre J, Charlotte F, Ghoussoub J-J, Fourcade C, Fischer A, Gandjbakhch I, Binet J-L, and Raphael M (1995). Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 13:961-968.
34. Liebowitz D, Kopan R, Fuchs E, Sample J, and Kieff E (1987). An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol 7:2299-2308.
35. Liebowitz D, Wang D, and Kieff E (1986). Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 58:233-237.
36. Lippman SM, Grogan TM, Carry P, Ogden DA, and Miller TP (1987). Post-transplantation T cell lymphoblastic lymphoma. Am J Med 82:814-816.
37. Martin J and Sugden B (1991). Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol 65:3246-3258.
38. Oldhafer KJ, Bunzendahl H, Frei U, Kemnitz J, Vogt P, and Pichlmayr R (1989). Primary Hodgkin's lymphoma: An unusual cause of graft dysfunction after kidney transplantation. Am J Med 878:218-220.
39. Palefsky JM, Berline J, Penaranda M-E, Lennette ET, Greenspan D, and Greenspan JS (1996). Sequence variation of latent membrane protein-1 of Epstein-Barr virus strains associated with hairy leukoplakia. J Infect Dis 173:710-714.
40. Peng M and Lundgren E (1992). Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7:1775-1782.
41. Peng-Pilon M, Ruuth K, Lundgren E, and Brodin P (1995). The cytoplasmic C-terminal domain but not the N-terminal domain of latent membrane protein 1 of Epstein-Barr virus is essential for B cell activation. J Gen Virol 76:767-777.
42. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977). Design and anlaysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39.
43. Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen YY, and Weiss LM (1992). Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992:327:1710-1714.
44. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular cloning: A laboratory manual (2nd ed). Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
45. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, and Kieff E (1990). Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084-4092.
46. Sandvej K, Peh S-C, Andresen BS, and Pallesen G (1994). Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84:4053-4060.
47. Santón A, Manzanal Al, Campo E, and Bellas C (1995). Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J Clin Pathol 48:M184-M187.
48. Sterling WA, Wu LYF, and Dowling EA (1974). Hodgkin's disease in a renal transplant recipient. Transplantation 17: 315-317.
49. Swerdlow SH (1992). Post-transplant lymphoproliferative disorders: A morphologic, phenotypic and genotypic spectrum of disease. Histopathology 20:373-385.
50. Trivedi P, Hu LF, Chen F, Christensson B, Masucci MG, Klein G, and Winberg G (1994). Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 30A:84-88.
51. Vasef MA, Kamel OW, Chen Y-Y, Medeiros LJ, and Weiss LM (1995). Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am J Pathol 147:1408-1415.
52. Wang D, Liebowitz D, and Kieff E (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
53. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R, Springer T, and Kieff E (1988). Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity. J Virol 62:4173-4184.
54. Wilson JB, Weinberg W, Johnson R, Yuspa S, and Levine AJ (1990). Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 61:1315-1327.
55. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, and Cohen JI (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080-1085.